Moreover, they suggested that surface functionalization could be used to specifically target receptors in BC, such as epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER-2), and fibroblast growth factor receptor 3 (FGFR-3), thereby increasing the efficacy and safety of the therapy [66]. The gene discussed is FGFR3; the disease is breast cancer.